Johnson & Johnson said on Monday it was in discussions with the U.S. Food and Drug Administration about rare cases of a neurological disorder, Guillain-Barre syndrome, that have been reported following vaccination with the Janssen COVID-19 vaccine.
The chance of having Guillain-Barre syndrome occur is very low and the rate of reported cases exceeds the background rate by a small degree, J&J said.
The statement follows a Washington Post report on Monday, which said the FDA was expected to announce a new warning on J&J’s coronavirus vaccine related to a rare autoimmune disorder.
Guillain-Barre syndrome is a rare neurological disorder in which th…
Keep on reading: Johnson & Johnson in discussion with FDA regarding COVID-19 vaccine side effects